FDA's Ongoing Scrutiny of Peptide Substances Raises Concerns for Compounding Pharmacies
The U.S. Food and Drug Administration (FDA) is intensifying its scrutiny of peptide substances under Section 503A of the Federal Food, Drug, and Cosmetic Act (FDCA). This section allows state-licensed pharmacies and physicians to compound drugs for individual patients without undergoing the new-drug approval process, provided certain conditions are met. The FDA is actively revisiting how it categorizes peptide substances, which are sorted into Category 1 (under evaluation) or Category 2 (significant safety risks). Recently, the FDA removed 12 peptides from Category 2, indicating they no longer present significant safety risks. However, these peptides have not been placed in Category 1 or on the FDA's 503A bulks list, leaving them in a legal gray area. This situation affects compounding pharmacies, telehealth platforms, and manufacturers, as they face enforcement risks if they compound or market these substances without FDA authorization.